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other factors, such as renin-angiotensin and thromboxane A2,
might have effects on cerebral microcirculation.5
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Vasodilatation after cardiac surgery
To the Editor:
Argenziano and associates,1 in their article on management
of vasodilatory shock after cardiac surgery, provide an excel-
lent study of enormous clinical importance. Identification of
low ejection fraction and angiotensin-converting enzyme
(ACE) inhibitors as risk factors for vasodilatory shock after
cardiopulmonary bypass (CPB) confirms the initial analysis
of 2729 patients undergoing CPB in our center.
However, the study raises a number of important issues that
were not mentioned:
While discussing the mechanisms for arginine vasopressin
deficiency, which may be multifactorial, the authors failed to
mention that angiotensin II decreases arginine vasopressin
release from the neurohypophysis.2 This implies that the
newer selective angiotensin II inhibitors like losartan may
also cause vasodilatory shock.
The majority of patients undergoing routine CPB, regard-
less of left ventricular function, have no sequelae if the ACE
inhibitor is withheld on the morning of the operation. With-
holding the ACE inhibitor also may decrease the chance of
renal complications via the reduced efferent arterial tone
caused by ACE inhibitors, which reduces glomerular filtra-
tion rate during CPB.3 Obviously, withholding the ACE in-
hibitor is not appropriate in patients awaiting cardiac trans-
plantation or left ventricular assist device implantation, but
the ACE inhibitor could be changed to a short-acting one
from the long-acting one that most patients receive.
Amiodarone, which is a noncompetitive α-blocker and β-
blocker, is commonly co-prescribed with ACE inhibitors in
patients with end-stage cardiac failure before heart transplan-
tation.4 Amiodarone has been shown to act synergistically
with ACE inhibitors in causing vasodilatory shock via a two-
hit mechanism.5 Unfortunately no mention was made of this.
Finally, nicorandil, a new potassium channel opener used
in the treatment of angina, in our experience, has been asso-
ciated with decreased systemic vascular resistance and
increased need for vasoconstrictor treatment.6 This seems to
be especially common when patients have taken a 10-mg
dose within 12 hours of CPB.
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Posterior aortoventricular bleeding after aortic valve
replacement with the stentless Cryolife-O’Brien
valve
To the Editor
Mediratta, Sosnowski, and Galiñanes1 have pointed out the
possibility of posterior aortoventricular bleeding after supra-
annular aortic valve replacement with a stentless prosthesis.
Such complications are directly related to extensive decalci-
fication of the aortic anulus (along the left coronary part of
the anulus).
We have now implanted nearly 400 Cryolife-O’Brien
valves (Cryolife International, Atlanta, Ga) in our hospital,
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